Not Everyone Should Get COVID Vaccine, States the Association of American Physicians and Surgeons (AAPS)
13 août 2021 12h48 HE | Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 13, 2021 (GLOBE NEWSWIRE) -- The voluntary COVID-19 vaccination program has failed to achieve 100 percent compliance, and coercive measures are increasing, even before any...
Sunshine Biopharma Logo
Sunshine Biopharma’s Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern
12 août 2021 09h00 HE | Sunshine Biopharma Inc.
MONTREAL, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Dyadic Logo Current.jpg
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
11 août 2021 08h35 HE | Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
27 juil. 2021 13h53 HE | FOMO CORP.
Chicago IL, July 27, 2021 (GLOBE NEWSWIRE) -- FOMO CORP. (OTC: FOMC) is pleased to announce that Retired Senator Gerald Dial (R: Alabama 13th District) has joined FOMO’s Advisory Board. Senator Dial...
Axiom Medical, an in
Axiom Medical, an innovator in occupational health services for employers, announced it has exceeded ten million check ins on the leading edge CheckIn2Work mobile app
20 juil. 2021 11h47 HE | Axiom Medical
Houston, TX, July 20, 2021 (GLOBE NEWSWIRE) -- CheckIn2Work reduces the risk of workplace COVID-19 and infectious disease outbreak with 24-7 mobile device-based self-service Daily Health...
Dyadic Logo Current.jpg
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
28 juin 2021 08h30 HE | Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...